EXEL Exelixis, Inc.
$71.74
Exelixis, Inc. (EXEL) Earnings News
Earnings press releases, previews and reviews for Exelixis, Inc. (EXEL), newest first. Our most recent is review: Exelixis Matches the Whisper as Cabometyx Growth Accelerates, but Zanzalintinib Delays and Flat Guidance Temper a Stock Near Its Highs.
Thursday
October 29, 2026
7:10 PM ET
Exelixis Matches the Whisper as Cabometyx Growth Accelerates, but Zanzalintinib Delays and Flat Guidance Temper a Stock Near Its Highs
Earnings Whispers · Review
Thursday
October 29, 2026
4:05 PM ET
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Wednesday
October 21, 2026
7:00 PM ET
Exelixis Faces a Test of Its Trimmed Outlook as Street Models Run Above Guidance
Earnings Whispers · Preview
Thursday
October 15, 2026
4:05 PM ET
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Wednesday
August 5, 2026
4:05 PM ET
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Wednesday
July 22, 2026
4:30 PM ET
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026